After Will Rosellini left the world of professional sports, he dedicated himself to science, a passion developed while watching some of the world’s best pitchers.
“I was curious how they could throw with the accuracy of a quarter of an inch, but I could only throw with the accuracy of three to four inches,” said Rosellini, CEO of MicroTransponder.
The former professional baseball player realized this tiny difference related to the nervous system. That discovery led him to start MicroTransponder, a company developing solutions to treat neurological disorders.
“What we’ve found in clinical studies is that by applying electricity to the vagus nerve we can open up a window in the brain with neurotransmitters that allow us to drive the brain to pay attention and learn faster,” said Rosellini.
MicroTransponder and research partner UT Dallas have quickly discovered their findings could potentially help people with a particular disorder.
“The place where that’s been immediately successful and applicable would be in the treatment of Tinnitus,” said Rosellini.
Tinnitus is not an ordinary ringing of the ears. It’s constant and can reach unbearable decibels, affecting the way of life for people like Phillip Lofton who suffers from Tinnitus.
“Because you suffer alone and nobody else can hear it, it’s hard for my family members and friends to understand it never, ever goes away,” said Lofton.
For twenty years Lofton has battled Tinnitus. The noise he hears has been measured at decibels equaling a jet engine. To Rosellini, that sound is a reminder of why he’s working so hard.
“For nearly two million people the tinnitus is so bad it affects them at work and for 15% of people of Tinnitus sufferers they’re emotionally disturbed by the suffering,” said Rosellini.
MicroTransponder has seen successful results on human patients in Belgium, and they are currently raising funds to be approved in the United States.
“For smaller companies that are doing medical products, we need to raise on the order of ten to twelve million dollars to get our product approved by the FDA,” said Rosellini.
Although MicroTransponder is in the early stages of fundraising and treatment, the company has big plans.
“We intend to restore or enhance the nervous system of one million patients worldwide,” said Rosellini.
And as long as he still suffers, Lofton says he wants to help find a solution.
Watch the video in HD above produced by DFW Reporting – the only news team in Texas that only reports on positive news!
Support our Journalist Angela Hamann on her official Facebook page: